Praxis Precision Medicines announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-lead managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Phase 2a results boosts credibility into readouts, says H.C. Wainwright
- Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
- Praxis Precision Medicines’ PRAX-628 shows high response in epilepsy study
- Praxis Precision Medicines to Host PRAX-628 Program Update
- Praxis Precision Medicines management to meet with Piper Sandler
